Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986460 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1: Sequence 1 | EXPERIMENTAL | - |
| Part 1: Sequence 2 | EXPERIMENTAL | - |
| Part 1: Sequence 3 | EXPERIMENTAL | - |
| Part 2: Treatment A | EXPERIMENTAL | - |
| Part 2: Treatment B | EXPERIMENTAL | - |
| Part 2: Optional Treatment C | EXPERIMENTAL | - |
| Part 2: Optional Treatment D | EXPERIMENTAL | - |
| Part 2: Optional Treatment E | EXPERIMENTAL | - |
| Administration of BMS-986460 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986460 | DRUG | Specified dose on specified days. |
Inclusion Criteria * Participants must be healthy as determined by no clinically significant deviation from normal in medical history, physical examination, vital signs, 12-lead ECGs, echocardiogram or clinical laboratory assessments, as determined by the investigator. * Participants must have a Bo...
BMS-986460 is an investigational small molecule being studied for metastatic castration-resistant prostate cancer. It is also being evaluated in healthy volunteers to assess the safety, tolerability, drug levels, and relative biological availability of alternate formulations. The drug is in Phase 1 clinical development and is not yet approved.
BMS-986460 is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with metastatic castration-resistant prostate cancer and in healthy volunteers.
BMS-986460 is in Phase 1 clinical development. It is being studied in two Phase 1 trials: one in patients with metastatic castration-resistant prostate cancer and one in healthy adult male participants. The drug is investigational and has not been approved by regulatory authorities.
BMS-986460 is being studied in two clinical trials. NCT06067841 is a Phase 1 study in participants with metastatic castration-resistant prostate cancer, currently recruiting in the United States, Canada, and France. NCT06877702 is a completed Phase 1 study in healthy adult male participants in the United States.
No alternative names for BMS-986460 have been disclosed. The drug is identified solely by its development code BMS-986460 in clinical trial registrations and by Bristol-Myers Squibb. It is a distinct investigational small molecule being evaluated for metastatic castration-resistant prostate cancer.